Are there clinical studies on Neuron Gold for nerve pain?
Executive summary
The available reporting shows active, peer-facing clinical work in neuromodulation from a company called Neuronoff—specifically first‑in‑human trials of an injectable electrode called the Injectrode for chronic low‑back pain (LIFE study) [1] [2] [3]. By contrast, there is no credible, independently reported clinical trial evidence for a consumer supplement or product explicitly branded “Neuron Gold” in the materials provided; the product’s own marketing claims clinical backing but the sources here do not document published clinical studies supporting that brand name [4] [5].
1. Neuronoff’s Injectrode: clinical work exists and is reported publicly
Neuronoff has completed first‑in‑human implants of its Injectrode device and reported that the Lumbar Injectrode Feasibility Evaluation (LIFE) study met its primary safety and secondary effectiveness goals in the initial cohort [1] [2]. Company materials and reporting describe 10 participants receiving temporary injectable electrodes near the dorsal rami for less than 30 days, with findings the company characterizes as demonstrating feasibility, safety and therapeutic‑level stimulation [3] [2]. Independent science reporting and NIH HEAL program summaries also describe academic collaborations and preclinical work supporting translation of the Injectrode concept [6] [7].
2. “Neuron Gold” as a supplement: claims versus documented evidence
The name “Neuron Gold” appears in direct‑to‑consumer marketing that asserts clinical backing and ingredient‑level evidence for nerve health, but the supplied product website and marketing pages do not point to peer‑reviewed clinical trials in the sources provided here [4] [5]. Those pages repeatedly state that ingredients are “clinically proven” or that the product is “based on clinical evidence,” but the reporting set includes no independent trial registries, journal publications, or investigator‑led clinical results verifying trials of a supplement called Neuron Gold [4] [5]. Therefore, while marketing claims clinical support, the supplied sources do not document actual clinical studies for that branded supplement.
3. A separate medical product named “M Neuron Gold” exists in prescription contexts
Separately, clinical and pharmaceutical databases list a prescription product called “M Neuron Gold,” which appears to be an injection formulation containing methylcobalamin (a form of vitamin B12) used for neuropathies and other conditions; these databases describe indications, dosing and side‑effect profiles rather than randomized controlled trials of the branded product [8] [9] [10]. The cited sources treat M Neuron Gold as a pharmaceutical formulation with routine clinical use information rather than as the target of new clinical efficacy trials presented here [8] [9].
4. Confusion, conflation and commercial incentives drive mixed messaging
The reporting bundle shows two distinct threads that can be easily conflated: (a) device‑centered clinical research by Neuronoff on an Injectrode neuromodulation therapy [1] [2] [3], and (b) consumer supplement marketing for “Neuron Gold” or later variants that tout clinical support without presenting trial publications in these sources [4] [5]. Additionally, there is legitimate preclinical interest in gold‑based nanotechnologies for neural modulation in the scientific literature—work that explores gold nanoparticles for neuronal interfacing—but those studies concern basic science rather than a marketed supplement called Neuron Gold [11]. Commercial websites naturally emphasize benefits and downplay gaps; the Neuron Gold marketing materials thus carry an implicit agenda to convert interest into sales absent peer‑reviewed clinical proof shown here [4] [5].
5. Bottom line and reporting limits
Based on the supplied reporting, there are documented first‑in‑human clinical studies for Neuronoff’s Injectrode neuromodulation device for chronic back pain [1] [2] [3], but no verifiable, independently reported clinical trials of a consumer supplement explicitly named “Neuron Gold” are present in these sources [4] [5]. There is a prescription injection product called M Neuron Gold described in drug databases with clinical usage information but not the kind of new randomized clinical trial evidence for a consumer supplement referenced by promotional claims in the provided materials [8] [9] [10]. If peer‑reviewed clinical trials of a supplement brand “Neuron Gold” exist, they are not included in the supplied reporting and would require searching clinical trial registries and medical journals beyond these sources.